AGS-009
AGS-009 is a humanized monoclonal neutralising antibody targeting IFN-α. AGS-009 significantly reduces activated lymphocytes, such as CD4+ and CD8+ T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgG4 kappa
Human
IFNA1
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Mathian A, et al. Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs. 2015 May;75(8):835-46. [Content Brief]
[2]. Carnathan D, et al. Reduced Chronic Lymphocyte Activation following Interferon Alpha Blockade during the Acute Phase of Simian Immunodeficiency Virus Infection in Rhesus Macaques. J Virol. 2018 Apr 13;92(9):e01760-17. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Powered by Bioz